← Back to Screener
Pulmatrix, Inc. Common Stock (PULM)
Price$1.25
Favorite Metrics
Price vs S&P 500 (26W)-78.66%
Price vs S&P 500 (4W)-45.44%
Market Capitalization$4.57M
All Metrics
Book Value / Share (Quarterly)$1.04
P/TBV (Annual)1.01x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.72%
Cash Flow / Share (Quarterly)$-1.49
Price vs S&P 500 (YTD)-46.59%
Net Profit Margin (TTM)-122.46%
EPS (TTM)$-1.41
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-1.41
Revenue Growth (5Y)-0.26%
EPS (Annual)$-1.41
ROI (Annual)-135.49%
Net Profit Margin (5Y Avg)-233.87%
Cash / Share (Quarterly)$1.12
ROA (Last FY)-124.72%
Revenue Growth TTM (YoY)-99.97%
EBITD / Share (TTM)$-1.47
ROE (5Y Avg)-84.77%
Operating Margin (TTM)-125.07%
Cash Flow / Share (Annual)$-1.49
P/B Ratio1.20x
P/B Ratio (Quarterly)2.14x
Net Income / Employee (Annual)$-3
EV / Revenue (TTM)0.06x
Net Interest Coverage (TTM)-127.50x
ROA (TTM)-88.53%
EPS Incl Extra (Annual)$-1.41
Current Ratio (Annual)12.55x
Quick Ratio (Quarterly)12.53x
3-Month Avg Trading Volume0.04M
52-Week Price Return-76.81%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$125.14
P/S Ratio (Annual)0.58x
Asset Turnover (Annual)0.79x
52-Week High$9.37
Operating Margin (5Y Avg)-221.49%
EPS Excl Extra (Annual)$-1.41
CapEx CAGR (5Y)46.00%
26-Week Price Return-74.67%
Quick Ratio (Annual)12.53x
13-Week Price Return-46.81%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.55x
Enterprise Value$0.477
Revenue / Share Growth (5Y)-25.66%
Asset Turnover (TTM)0.46x
Book Value / Share Growth (5Y)-39.42%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-122.46%
Cash / Share (Annual)$1.12
3-Month Return Std Dev119.14%
Net Income / Employee (TTM)$-3
ROE (Last FY)-135.49%
Net Interest Coverage (Annual)-45.32x
EPS Basic Excl Extra (Annual)$-1.41
Receivables Turnover (TTM)6.56x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.41
Receivables Turnover (Annual)16.82x
ROI (TTM)-96.97%
P/S Ratio (TTM)0.58x
Pretax Margin (5Y Avg)-233.87%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$125.14
Price vs S&P 500 (52W)-106.64%
Year-to-Date Return-43.95%
5-Day Price Return-0.79%
EPS Normalized (Annual)$-1.41
ROA (5Y Avg)-68.55%
Net Profit Margin (Annual)-122.46%
Month-to-Date Return-3.10%
Cash Flow / Share (TTM)$-4.42
EBITD / Share (Annual)$-1.47
Operating Margin (Annual)-125.07%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-84.77%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.41
P/TBV (Quarterly)1.01x
P/B Ratio (Annual)2.14x
Pretax Margin (TTM)-122.46%
Book Value / Share (Annual)$1.04
Price vs S&P 500 (13W)-47.50%
Beta2.07x
P/FCF (Annual)1.44x
Revenue / Share (TTM)$0.00
ROE (TTM)-96.97%
52-Week Low$1.16
Analyst Recommendations
Dec 2024
Jan 2025
Feb 2025
Mar 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PULMPulmatrix, Inc. Common Stock | 0.58x | -99.97% | — | — | $1.25 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Pulmatrix is a biopharmaceutical company developing inhaled therapies for migraine and respiratory diseases using its proprietary iSPERSE dry powder delivery platform. Its clinical pipeline includes PUR3100 for acute migraine, PUR1800 for COPD exacerbations, and PUR1900 for aspergillosis in asthma and cystic fibrosis patients, targeting significant unmet medical needs.